Leerink Partners analyst Christopher Liu maintained a Buy rating on Arvinas Holding Company (NASDAQ:ARVN) on Thursday, setting a price target of $115, which is approximately 36.30% above the present share price of $84.37.
Liu expects Arvinas Holding Company to post earnings per share (EPS) of -$0.94 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Arvinas Holding Company, with an average price target of $115.
The analysts price targets range from a high of $120 to a low of $110.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $9.28 million and a net profit of -$47.33 million. The company's market cap is $4.46 billion.
According to TipRanks.com, Leerink Partners analyst Christopher Liu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.2% and a 40.00% success rate.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.